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ardiovascular disease is the leading
cause of morbidity and mortality in
patients with diabetes (1). The con-
comitant presence of multiple classical
cardiovascular risk factors in diabetic
subjects contributes to enhanced athero-
thrombotic risk (2). However, other risk
factors may be important such as abnor-
malplateletfunction(3).Platelets,infact,
play a key role in atherogenesis, and its
thrombotic complications and measures,
which lead to blockade of one or multiple
pathways modulating platelet activation
and aggregation processes, are pivotal in
reducing ischemic risk in diabetic sub-
jects (4). This article reviews currently
available antiplatelet agents on ischemic
events in diabetic patients, limitations of
currently available treatment strategies,
and antiplatelet agents currently under
clinical development that may potentially
overcome these limitations.
Antiplatelet therapy
There are three different classes of plate-
let-inhibiting drugs: cyclooxygenase-1
(COX-1) inhibitors (aspirin), ADP P2Y12
receptor antagonists (thienopyridines),
and platelet glycoprotein (GP) IIb/IIIa in-
hibitors, which are mostly used for the
prevention and treatment of athero-
thrombotic disorders (4) (Fig. 1). Aspirin
inhibits the COX-1 enzyme and therefore
blocks platelet thromboxane A2 synthesis
(5).However,patientsonaspirintherapy,
particularly those at high risk, may con-
tinue to have recurrent thrombotic
events. GP IIb/IIIa inhibitors are very po-
tent antiplatelet agents, which exert ef-
fects through inhibition of the ﬁnal
common pathway that mediates platelet
aggregation processes, and have been
shown to be effective in preventing
thrombotic complications in high-risk
patients undergoing percutaneous coro-
nary interventions (PCI) (4). However,
these agents are available only for paren-
teral use and have a short duration of ac-
tion, which impedes their use for long-
term protection. The need for alternative
antiplatelet treatment strategies led to the
evaluationofeffectsobtainedfromacom-
bination of oral antiplatelet agents inhib-
iting other platelet-activating pathways.
Ticlopidineisaﬁrst-generationthienopy-
ridine, which irreversibly blocks the
platelet ADP P2Y12 receptor (6). Its com-
bination with aspirin is associated with a
more enhanced inhibition of platelet
function and better clinical outcomes in
patients undergoing coronary stenting
compared with aspirin monotherapy or
aspirin plus warfarin (6). However, the
limited safety proﬁle of ticlopidine and its
inability to achieve antiplatelet effects
rapidly have led clopidogrel, a second-
generation thienopyridine, to become the
ADP P2Y12 receptor antagonist of choice
(6–7).
Aspirin. Aspirin selectively acetylates
the COX-1 enzyme, thereby blocking the
formation of thromboxane A2 in platelets
(5). This effect is irreversible because
platelets are enucleate and, thus, unable
to resynthesize COX-1. In addition to be-
ingtheantiplateletagentofchoiceforsec-
ondary prevention of ischemic events in
patients with atherosclerotic disease, as-
pirin may also be used for primary pre-
vention of ischemic events. In fact,
although this indication in the general
populationiscontroversial,thereisanex-
pert consensus for aspirin usage in the
primary prevention setting in diabetic
patients.
Aspirin as a primary prevention strat-
egy in diabetes. The American Diabetes
Association (ADA) recommends the use
of low-dose aspirin (75–162 mg/day) as a
primary prevention strategy in patients
withtype1ortype2diabetesatincreased
cardiovascular risk, including those 40
years of age or who have additional risk
factors (family history of cardiovascular
disease, hypertension, smoking, dyslipi-
demia, or albuminuria) (8). However,
aspirin therapy should not be recom-
mended for patients aged 21 years be-
cause this may increase the risk of Reye’s
syndrome. The role of aspirin in diabetic
patients aged 30 years remains unclear
because it has not been investigated.
Several clinical trials have evaluated
the efﬁcacy of aspirin in diabetic patients
(9–12). Most of these studies showed a
beneﬁt of aspirin in diabetic patients (9–
11).However,theseoutcomeswerebased
on post hoc analyses because these trials
werenotspeciﬁcallydesignedfordiabetic
patients. In addition, the obtained results
were based on small numbers of subjects,
which may explain why aspirin was not
always shown to be beneﬁcial in the pri-
mary prevention setting in diabetic pa-
tients (12).
The Japanese Primary Prevention of
Atherosclerosis With Aspirin for Diabetes
(JPAD) trial (clinical trial reg. no.
NCT00110448) was the ﬁrst prospec-
tively designed trial to evaluate the use of
aspirin (81 mg or 100 mg) in the primary
preventionofcardiovasculareventsinpa-
tients with type 2 diabetes (n  2,539)
aged 30–85 years in Japan (13). After a
medianfollow-upof4.37years,therewas
a 20% difference between the aspirin and
nonaspirin arms in the primary end point
(5.4 vs. 6.7%, respectively) that failed to
achieve statistical signiﬁcance (P0.16).
Among patients aged 65 years (n 
1,363),aspirinwasassociatedwitha32%
reduction in the risk of the primary end
point (6.3 vs. 9.2%; P  0.047). Further-
more, in aspirin-treated patients, the
incidence of fatal coronary and cerebro-
vascular events (a secondary end point)
was signiﬁcantly lower by 90% (0.08 vs.
0.8%; P  0.0037); however, there were
no differences in nonfatal coronary and
cerebrovascular events. Aspirin was well
tolerated, with no signiﬁcant increase in
the composite of hemorrhagic stroke and
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tions of this trial include the open-label
assignment to aspirin and the low event
rate. Therefore, the study may have been
underpowered to demonstrate a signiﬁ-
cant effect of aspirin on the primary end
point. The results of this trial have ques-
tioned the validity of current guideline
recommendationsonaspirinusageinpri-
mary prevention in diabetic patients.
However, there are other ongoing trials,
which will provide further insights to the
appropriateness of aspirin usage in the
primary prevention setting in diabetic
subjects.TheseincludeAStudyofCardio-
vascular Events iN Diabetes (ASCEND) (clin-
ical trial reg. no. NCT00135226) and Aspirin
and Simvastatin Combination for Cardiovas-
cular Events Prevention Trial in Diabetes
(ACCEPT-D) (clinical trial reg. no. IS-
RCTN48110081).
Recently,theresultsofthePrevention
OfProgressionofArterialDiseaseAndDi-
abetes (POPADAD) trial have been re-
ported (14). In this trial, patients (n 
1,276)withtype1ortype2diabetesaged
40 years with an ankle-brachial pres-
sure index 0.99 but no symptomatic
cardiovascular disease were randomized
to aspirin (100 mg) and antioxidants in a
double-blind, 2  2 factorial, placebo-
controlled fashion. This trial failed to
show any beneﬁt with aspirin or antioxi-
dants in primary prevention of cardiovas-
cular events. The overall small number of
patients with low event rates could have
playedaroleintheoutcomesofthestudy.
Although patients in this trial were
asymptomatic, this should not be consid-
ered a primary prevention study because
subjects had some degree of peripheral
arterial disease (PAD).
Aspirin as a secondary prevention
strategy in diabetes. ADA recommends
the use of low-dose aspirin (75–162 mg/
day) for secondary prevention of cerebro-
vascular and cardiovascular events in all
diabetic patients (8). This position is sup-
ported by the results of two large meta-
analyses of major secondary prevention
trialsbytheAntithromboticTrialists’Col-
laboration (ATC), which showed oral an-
tiplatelet agents, mostly aspirin, to be
protective in patients at high risk for car-
diovascular disease, including those with
diabetes (15–16). The meta-analyses in-
cluded 287 secondary prevention trials
involving212,000high-riskpatientswith
acute or prior vascular disease or another
condition that increased their risk of vas-
cular disease. Aspirin in doses ranging
from 75 to 325 mg/day was the most fre-
quentlyusedantiplateletagent.Inthema-
jor high-risk groups (acute myocardial
infarction, past history of myocardial in-
farction,pasthistoryofstrokeortransient
ischemic attack, acute stroke, and any
otherrelevanthistoryofvasculardisease),
antiplatelet therapy reduced the inci-
denceofvasculareventsby23%.Ofnote,
a low dose of aspirin (75–150 mg/day)
was found to be at least as effective as
higher daily doses. Furthermore, bleed-
ing complications were reduced with the
lower doses. In more than 4,500 diabetic
patientsstudiedintheATC,theincidence
of vascular events was also reduced from
23.5 in the control group to 19.3% in the
group treated with antiplatelet therapy
(P  0.01) and from 17.2 to 13.7% in the
42,000 nondiabetic patients (P 
0.00001). Although the overall incidence
of vascular events was much higher in di-
abetic patients, the beneﬁt of antiplatelet
therapy in both diabetic and nondiabetic
patients was consistent (42 vascular
events were prevented for every 1,000 di-
abetic patients and 35 events for every
1,000 nondiabetic patients).
P2Y12 receptor antagonists
Clopidogrel is currently the thienopyri-
dineofchoicebecauseithasamorefavor-
able safety proﬁle compared with that of
ticlopidine(6–7).TheClopidogrelversus
Aspirin in Patients at Risk of Ischemic
Events (CAPRIE) trial examined the ef-
fects of clopidogrel (75 mg/day) versus
aspirin (325 mg/day) in a large secondary
prevention population (n  19,185) of
patients with a history of recent myocar-
dial infarction, recent ischemic stroke, or
established PAD (17). The annual inci-
dence of the primary end point (com-
bined incidence of vascular death,
myocardialinfarction,orischemicstroke)
was 5.32% with clopidogrel and 5.83%
with aspirin, representing an 8.7% rela-
tive risk reduction in favor of clopidogrel
(P  0.043). Bhatt et al. (18) retrospec-
tively analyzed the results of the diabetic
subgroup in the CAPRIE study, which
represented20%ofthestudypopulation.
The composite vascular primary end
point occurred in 15.6 and 17.7% of pa-
tients randomized to clopidogrel and as-
Figure1—Mechanismsofactionofantiplateletagents.AspirininhibitsthromboxaneA2(TXA2)
synthase through blockade of the COX-1 enzyme. Picotamide, ramatroban, and ridogrel inhibit
both TXA2 synthase and TXA2 receptors. Thienopyridines, ticlopidine, and clopidogrel are inhib-
itors of ADP P2Y12 receptor and block intracellular pathways leading to platelet activation.
Prasugrel, ticagrelor, cangrelor, and elinogrel are P2Y12 receptor antagonists currently under
clinical investigation. Aspirin and P2Y12 receptor antagonists have synergistic effects in blocking
the ﬁnal common pathway leading to platelet aggregation represented by GP IIb/IIIa receptor,
which may be directly inhibited by intravenous GP IIb/IIIa receptor antagonists. Cilostazol is an
inhibitor of phosphodiesterase (PDE) III, which inhibits platelets through an increase in in-
traplateletcAMPlevels.E5555andSCH530348arethrombinreceptorantagoniststhatblockthe
PAR-1 subtype. (Adapted from Schafer AI: Antiplatelet therapy. Am J Med 101:199–209, 1996.)
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1,000 diabetic patients treated, this led to
21 vascular events prevented, which in-
creased to 38 among insulin-treated dia-
betic patients. Of note, the reduction in
thecompositevascularprimaryendpoint
with clopidogrel (11.8%) compared with
aspirin (12.7%) was not statistically sig-
niﬁcantinnondiabeticpatients.ADAcur-
rently recommends the use of clopidogrel
therapyinveryhigh-riskdiabeticpatients
or as an alternative therapy in aspirin-
intolerant patients (8).
The Clopidogrel in Unstable Angina
to Prevent Recurrent Events (CURE)
study examined outcomes with clopi-
dogrel plus aspirin versus aspirin alone in
patients (n  12,562) with unstable an-
gina or non–ST-elevation myocardial in-
farction (NSTEMI) (19). Patients were
randomized to treatment with either clo-
pidogrel (300 mg loading dose and 75
mg/day maintenance dose) or placebo in
addition to standard aspirin therapy (75–
325 mg/day) for up to 1 year. Patients
assigned to treatment with dual antiplate-
lettherapy(aspirinandclopidogrel)hada
signiﬁcant 20% relative reduction in the
ﬁrst primary outcome (composite vascu-
lar death, myocardial infarction, or
stroke) compared with that in patients
treated solely with aspirin (9.3 vs. 11.4%,
respectively; P  0.001). Although the
enhanced degree of platelet inhibition as-
sociated with dual antiplatelet therapy
reduced ischemic events, this was associ-
ated with a higher incidence of major
bleeding(3.7vs.2.7%;P0.001).How-
ever, there were no signiﬁcant differences
inlife-threateningbleeding(2.2vs.1.8%;
P  0.13). In the CURE study, there were
2,840 diabetic patients who experienced
17% reduction in the ﬁrst primary out-
come when treated with combined aspi-
rin and clopidogrel therapy compared
withaspirinalone(14.2vs.16.7%).How-
ever, the CI 0.70–1.02 shows that, al-
though dual antiplatelet therapy with
aspirin and clopidogrel provided beneﬁ-
cial effects in the diabetic subgroup (as
in the overall study population), this
achieved a borderline statistical signiﬁ-
cance. It is important to note that the
eventratewasmuchhigherinthediabetic
than in the nondiabetic subgroup despite
more intense antiplatelet therapy with
the adjunctive use of clopidogrel. In fact,
the primary composite cardiovascular
end point was almost twofold higher in
diabetic than in nondiabetic patients
(14.2 vs. 7.9%, respectively) (19). These
ﬁndings emphasize that more speciﬁc an-
tiplatelet treatment regimens, which may
includemorepotentagentsoracombina-
tion with other antiplatelet drugs, are
warranted in diabetic patients (20).
The current American College of
Cardiology (ACC)/American Heart As-
sociation (AHA) guidelines for the
management of unstable angina and
NSTEMI recommend the addition of clo-
pidogrel (300 mg loading dose and 75
mg/day maintenance dose) to aspirin in
patients presenting with unstable angina
and NSTEMI (21). Recently, the use of
clopidogrel in patients with ST-elevation
myocardial infarction (STEMI) has been
approved by the U.S. Food and Drug Ad-
ministration and endorsed by the current
ACC/AHAguidelinesonthemanagement
of STEMI patients (22). In acute coronary
syndrome(ACS)patients,guidelinesstate
that clopidogrel should be used regard-
less of the treatment strategy adopted
(invasiveornoninvasive)andshould,ide-
ally, be continued for up to 1 year. The
prognostic implications of compliance
with adjunctive clopidogrel therapy are
underscored by a rebound increase in
death and myocardial infarctions follow-
ing its withdrawal (23). This phenome-
non is particularly apparent in diabetic
patients and may be attributed to a more
marked increase in platelet reactivity in
thesepatientsfollowingclopidogrelwith-
drawal (23–24).
In contrast to the clear beneﬁt seen
with dual antiplatelet therapy across the
spectrum of patients with ACS, including
those undergoing PCI, the results of the
Clopidogrel for High Atherothrombotic
Risk and Ischemic Stabilization, Manage-
ment, and Avoidance (CHARISMA) trial
showedthatinhigh-riskbutnonacutepa-
tients(n15,603)withclinicallyevident
cardiovascular disease (n  12,153) or
multiple cardiovascular risk factors (n 
3,284), treatment with clopidogrel plus
aspirin was not signiﬁcantly more effec-
tive than that with aspirin alone in reduc-
ing the rate of cardiovascular death,
myocardial infarction, or stroke (6.8 vs.
7.3%, respectively; P  0.22) (25). Al-
though a subgroup analysis in a higher-
risk group (n  9,478) with prior
myocardialinfarction,ischemicstroke,or
symptomatic PAD (“CAPRIE-like” popu-
lation) showed a 17% relative risk reduc-
tion (P  0.01) with dual antiplatelet
therapy (26), the opposite ﬁndings were
observed in patients in the lower-risk co-
hortwhowereenrolledinthestudybased
on the presence of multiple cardiovascu-
lar risk factors in which an increase in
mortality was observed. Importantly, a
large number of patients enrolled in this
latter subgroup had diabetes, as diabetes
diagnosis represented one of the key in-
clusion criteria. Therefore, dual antiplate-
let therapy with aspirin and clopidogrel
shouldnotbeadvocatedintheprimarypre-
vention setting for diabetic individuals.
GP IIb/IIIa receptor antagonists
Numerous studies have been performed
comparing various GP IIb/IIIa inhibitors.
Currently, three different GP IIb/IIIa in-
hibitors (abciximab, eptiﬁbatide, and ti-
roﬁban)areapprovedforclinicaluse.Ina
meta-analysis of six trials of intravenous
GP IIb/IIIa inhibitors in ACS patients,
22% of whom had diabetes (n  6,458),
GP IIb/IIIa blockers signiﬁcantly reduced
mortality at 30 days from 6.2 to 4.6%
(P  0.007) in diabetic patients (27).
Among more than 22,000 patients in
these trials who did not have diabetes, GP
IIb/IIIa inhibitors did not improve sur-
vival.TheeffectofGPIIb/IIIainhibitorsin
diabetic individuals was even greater in
1,279 patients who underwent percuta-
neous coronary intervention during the
index hospitalization; in these individu-
als, GP IIb/IIIa inhibitors reduced 30-day
mortality from 4 to 1.2% (P  0.002). Of
note,thesetrialswereperformedinanera
oflimiteduseofclopidogrelthathaschal-
lenged the need for a GP IIb/IIIa receptor
antagonistindiabeticpatients.Infact,the
Intracoronary Stenting and Antithrom-
botic Regimen: Is Abciximab a Superior
Way to Eliminate Elevated Thrombotic
RiskinDiabetics?(ISAR-SWEET)trialdid
not show any effect of abciximab on
1-year risk of death and myocardial in-
farctionindiabeticpatients(n701)un-
dergoing PCI after pretreatment with a
600-mg loading dose of clopidogrel at
least 2 h before the procedure (28). How-
ever, the Intracoronary Stenting and An-
tithrombotic Regimen: Rapid Early
Action for Coronary Treatment 2 (ISAR-
REACT 2) trial clearly showed that abcix-
imab safely reduces the risk of adverse
events in patients with NSTEMI ACS un-
dergoing PCI after pretreatment with 600
mg of clopidogrel, which was adminis-
tered to patients with elevated troponin
levels but not to patients with electrocar-
diogram changes (29). The beneﬁt was
observed across all subgroups, includ-
ing patients with diabetes. Overall, in
accordance with current guidelines,
these results continue to support the
use of GP IIb/IIIa receptor antagonists
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diabetes (21).
Increasedbleedingratesrepresentthe
major limitation of GP IIb/IIIa agents.
Thereisincreasingevidencethatbleeding
hasanimportantimpactonprognosis,in-
cluding long-term mortality (30). Com-
pared with GP IIb/IIIa inhibitors,
bivalirudin (a direct thrombin inhibitor)
hasbeenshowntoprovidesimilarprotec-
tion from ischemic events with less major
bleeding in ACS patients, resulting in a
signiﬁcant reduction in net adverse clini-
cal outcomes (31). These ﬁndings were
corroborated in a recent subgroup anal-
ysis of the Acute Catheterization and
Urgent Intervention Triage Strategy
(ACUITY) trial performed in the diabetic
cohort (n  3,852). In particular, biva-
lirudin monotherapy compared with GP
IIb/IIIa plus heparin resulted in a similar
rate of composite ischemia (7.9 vs. 8.9%,
respectively; P  0.39) and less major
bleeding(3.7vs.7.1%;P0.001),yield-
ing fewer net adverse clinical outcomes
(10.9 vs. 13.8%; P  0.02) (32).
Limitations of currently available
antiplatelet drugs
Aspirinandclopidogrelrepresentthecor-
nerstone of treatment for secondary pre-
vention of ischemic events in patients,
including those with diabetes, presenting
with either stable or unstable atheroscle-
rotic cardiovascular disease. However, a
considerablenumberofpatientscontinue
toexperiencerecurrentatherothrombotic
eventsdespitetheuseoftheseantiplatelet
agents. These observations have led over
the course of recent years to the develop-
ment of the concept of antiplatelet drug
resistance. The term “resistance” derives
from a laboratory ﬁnding consisting in
failure of an antiplatelet agent to ade-
quately block its speciﬁc target on the
platelet (33). Therefore, thrombotic
events cannot be attributed to drug resis-
tance if the efﬁcacy of the antiplatelet
agent was not tested in affected patients.
For aspirin, resistance involves inade-
quate or lack of inhibition of the COX-1–
mediated thromboxane A2 pathway,
whereas for clopidogrel, resistance in-
volves P2Y12 receptor signaling (33). An-
tiplatelet drug resistance should not be
confused with treatment failure, which is
deﬁned by recurrence of an ischemic
event despite treatment. Indeed, anti-
plateletdrugresistancecanleadtoatreat-
mentfailure,butnotalltreatmentfailures
can be attributed to antiplatelet drug re-
sistance. This is in line with the multifacto-
rial nature of atherothrombosis, which
implies the existence of multiple mecha-
nisms that can lead to recurrence of events.
Aspirin resistance. Numerous studies
have correlated aspirin resistance with
long-term adverse clinical outcomes not
only in patients with coronary artery dis-
ease but also in individuals with ischemic
stroke or peripheral arterial disease (33).
The prevalence of aspirin resistance de-
scribed in the literature varies consider-
ably (in 0% of patients in some studies
and 50% of patients in others); the dis-
parateﬁndingscanbeattributedtodiffer-
ences in the deﬁnition of resistance, type
of assay used, dose of aspirin, and patient
population under consideration. Many of
the studies used assays that are not
COX-1 speciﬁc (e.g., PFA-100, light
transmittance aggregometry using ago-
nistsotherthanarachidonicacid),andthe
results obtained may be reﬂective of mul-
tiple platelet-signaling pathways. These
tests typically lead to a higher prevalence
of aspirin resistance, particularly in dia-
betic patients (34). There is accumulating
evidence, however, that when tests that
speciﬁcallyassessCOX-1activityareused
todetermineaspirinresponsiveness,aspi-
rin resistance is encountered very infre-
quently (in 5% of patients) (35–36).
Even though the relevance of different as-
says testing aspirin sensitivity (speciﬁc
and nonspeciﬁc for COX-1 inhibition)
still needs to be better deﬁned, meta-
analyses using various laboratory assays
support the poor prognostic implications
of inadequate aspirin-induced effects
(37–38). However, there are no pub-
lished studies speciﬁcally designed to
evaluate the implications of biochemical
aspirin resistance in diabetic patients.
The foremost reason for aspirin resis-
tance when using COX-1–speciﬁc assays
ispoorpatientcompliance(33,35).Inter-
actions with drugs, such as ibuprofen,
that interfere with aspirin–induced
COX-1 acetylation may also be a cause of
inadequate or absent effects of aspirin
(39). The latter may also be responsible
for an increased risk of ischemic events
despite aspirin use. In addition, the over-
all prevalence of inadequate aspirin ef-
fects may be inﬂuenced by the patient
population under investigation. Patients
with diabetes are typically characterized
by platelet hyperreactivity. Although as-
pirin may lead to complete blockade of
COX-1 as assessed by assays speciﬁc to
thistarget,highresidualplateletreactivity
may persist in these patients as a result of
upregulationofothersignalingpathways,
which are not blocked by aspirin. This
becomesmoreevidentwhennon–COX-1
speciﬁc assays are used, and diabetic pa-
tients are more likely to be resistant using
these tests (34).
Only a limited number of studies
have investigated the potential mecha-
nisms of aspirin resistance intrinsic to di-
abetic patients. Diabetic individuals are
characterized by increased platelet reac-
tivityandanincreasedlevelandactivityof
prothrombotic clotting factors (4), which
may explain their predisposition to inad-
equate aspirin-induced effects. Hypergly-
cemia may be considered a diabetes-
speciﬁc mechanism for inadequate
aspirin-induced effects (40). In fact, an
interaction between glycation and acety-
lation has been repeatedly shown. Also,
increased glycation of platelet and coagu-
lation factor proteins may interfere with
the acetylation process, thereby contrib-
uting to inadequate aspirin-induced anti-
platelet effects in diabetic patients.
However, it still remains undetermined
whether improved glycemic control en-
hances the efﬁcacy of aspirin or whether
increaseddosesofaspirinarebeneﬁcialin
the presence of poor glycemic control.
Clopidogrel resistance. Clopidogrel is
a speciﬁc, irreversible antagonist of the
plateletP2Y12ADPreceptorand,thus,in-
hibitsplateletactivationinanentirelydis-
tinct manner compared with that of
aspirin. Similarly to aspirin, the preva-
lenceofclopidogrelresistancereportedin
the literature varies considerably and is
related to differences in the deﬁnitions
used, type of assay used, dose of clopi-
dogrel, and patient population (41).
Nonetheless, interindividual variability in
platelet response to clopidogrel is a well-
established concept. Genetic, cellular, and
clinical causes can all contribute to inade-
quate clopidogrel responsiveness (41). The
presence of diabetes may contribute to in-
adequate clopidogrel-induced effects
through various mechanisms (Table 1).
Clopidogrel nonresponsiveness is more
prevalent in diabetic compared with non-
diabeticpatientsandishighestamongpa-
tients requiring insulin therapy (42–44)
(Fig. 2). These ﬁndings may explain why
diabetic patients, particularly those at the
most advanced state of their disease (e.g.,
insulin-requiring diabetes), continue to
have recurrent atherothrombotic events,
including stent thrombosis (41,45).
Platelet-function proﬁling performed ex-
clusively in type 2 diabetic patients re-
ceiving aspirin and clopidogrel therapy
has shown that even though these pa-
Antiplatelet therapy in diabetes
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jects have higher degrees of platelet
reactivity, there is still a broad range of
responsiveness (46). Importantly, within
this cohort composed only of diabetic pa-
tients, those with high platelet reactivity
had a more than threefold risk of long-
term adverse events (Fig. 3) (46). These
patients were also characterized by a gen-
eral dysfunctional status of their platelets,
as revealed by the presence of high plate-
let reactivity using agonists testing for
multiple signaling pathways.
Numerous mechanisms may account
forinadequateclopidogrelresponseindi-
abetic patients, in particular type 2 dia-
beticsubjects.Humanplateletsaretargets
of insulin, which interacts with its own
receptor on the surface of the platelet,
leading to loss of Gi activity. This results
in suppression of cAMP, inhibition of
P2Y12 signaling, and reduced platelet re-
activity (47–48). However, platelets of
type 2 diabetic patients are also affected
by the insulin resistance phenomenon
that characterizes these patients, which
results in decreased sensitivity to insulin
(9). This results in upregulation of the
P2Y12 pathway and increased platelet re-
activity. Other mechanisms linked to clo-
pidogrel nonresponsiveness in diabetic
patients include increased exposure to
ADP, increased cytosolic levels of calcium,
and increased platelet turnover (4,41).
Future directions
The limitations of currently available an-
tiplatelet agents that are used for preven-
Table 1—Mechanisms of clopidogrel response variability
Clinical factors
Failure to prescribe/poor compliance
Underdosing
Poor absorption
Drug–drug interactions involving intestinal P-glycoprotein (MDR1 gene product)
Drug–drug interactions involving CYP3A4
Acute coronary syndrome
Diabetes/insulin resistance*
Elevated BMI*
Cellular factors
Accelerated platelet turnover*
Reduced CYP3A metabolic activity*
Increased ADP exposure*
Upregulation of the P2Y12 pathway*
Upregulation of the P2Y1 pathway*
Upregulation of P2Y-independent pathways*
Genetic factors
Polymorphisms of CYP
Polymorphisms of GPIa
Polymorphisms of P2Y12
Polymorphisms of GPIIIa
Polymorphisms of MDR1
*Factors potentially leading to reduced clopidogrel-induced effects in diabetic subjects. CYP, cythochrome
P450; MDR1, multidrug resistance protein 1. (Adapted from ref. 41.)
Figure 2— Platelet aggregation following ADP (20 mol/l) stimuli in nondiabetic patients (NDM) (n  65), non–insulin-treated diabetic patients
(NITDM) (n  133), and insulin-treated diabetic patients (ITDM) (n  68). Platelet aggregation is higher in diabetic than in nondiabetic patients,
and insulin-treated diabetic patients have the highest degree of platelet reactivity. Platelet aggregation progressively increases across nondiabetic,
non–insulin-treated, and insulin-treated patients, respectively. (Adapted from ref. 43.)
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have been shown to be of greater magni-
tude among diabetic patients underscore
the need for more speciﬁc antiplatelet
treatment regimens, particularly in these
patients. Three strategies are proposed to
achieve this goal and include dose modi-
ﬁcation, adjunctive antiplatelet drug us-
age, and use of newer agents.
Antiplatelet drug dose modiﬁcation.
The rationale behind increasing the dose
ofcurrentlyavailableantiplateletagentsis
that this strategy may potentially increase
the bioavailability of the drug and there-
fore enhance platelet inhibition. The dose
ofaspirinusedinclinicalpracticebroadly
varies (75–325 mg/daily). Although there
are no randomized studies assessing
which of these doses is most effective, the
ATC clearly shows that higher aspirin
doses are not associated with better clini-
cal outcomes (15–16). On the contrary,
aspirin dose is associated with a higher
risk of adverse effects, mainly gastrointes-
tinal bleed (5). Although functional stud-
ies have shown that aspirin dosing may
have an impact on its COX-1–indepen-
dent effects, the signiﬁcance of which is
unknown, this does not affect the degree
of COX-1 blockade, which requires that
low doses of aspirin be fully inhibited (5).
Giventhatdiabeticplateletsarecharacter-
izedbyincreasedturnoverrates(4),ithas
beenadvocatedthatmultipledailydosing
rather than an increase in a once-daily
dose may be more beneﬁcial in these pa-
tients. Aspirin, in fact, has a very short
half-life and therefore will not achieve
blockade of newly generated platelets.
However, the functional and clinical im-
plications of once-daily versus multiple
daily aspirin administrations are un-
known.
Several studies have focused on how
to overcome clopidogrel nonresponsive-
ness by increasing the dose (49–50). The
Optimizing Anti-Platelet Therapy in Dia-
betes MellitUS (OPTIMUS) study selec-
tively examined type 2 diabetic patients
with high platelet reactivity in their
chronic phase of clopidogrel treatment
(50). The use of a 150-mg clopidogrel
maintenance dose resulted in greater
platelet inhibition than use of a 75-mg
dose.Recentﬁndingshaveshownthaten-
hanced P2Y12 inhibition achieved with
high-dose clopidogrel in diabetic patients
also reduces thrombin generation (51).
However, despite this strategy, a signiﬁ-
cant number of patients remained above
the therapeutic threshold of posttreat-
ment platelet reactivity adopted in this
study (50,52). Despite the lack of large-
scale clinical trial data sufﬁciently pow-
ered to assess the safety and efﬁcacy of
high-dose clopidogrel, PCI guidelines
provideaclassIrecommendation(levelof
evidenceC)forhigh(600mg)clopidogrel
loading doses (53). A class IIb level of ev-
idence C is available for 150-mg mainte-
nance dose. The ongoing Clopidogrel
Optimal Loading Dose Usage to Reduce
Recurrent EveNTs/Optimal Antiplatelet
Strategy for InterventionS (CURRENT/
OASIS7) trial will evaluate whether high
loading and maintenance dosing of clopi-
dogrel achieves better clinical outcomes
than standard dosing in ACS patients un-
dergoing PCI (clinical trial reg. no.
NCT00335452). In addition, all patients
will be randomized to receive low (75–
100 mg) or high (300–325 mg) doses of
aspirin.
Use of adjunctive antiplatelet agents.
Using additional antiplatelet therapy on
top of therapies currently used for sec-
ondary prevention of ischemic events
may be a way of achieving enhanced
platelet inhibition in diabetic patients.
However, there are limited options to
reach this goal. GP IIb/IIIa inhibitors us-
age is limited to the acute phase of ther-
apy. These drugs have been shown to be
particularlybeneﬁcialinACSpatientsun-
dergoing PCI, in particular diabetic pa-
tients (27). However, in the current era of
high-dose clopidogrel usage, GP IIb/IIIa
inhibitors failed to show any clinical ben-
eﬁt in non-ACS settings, including in di-
abetic patients (28). It has been recently
suggested that GP IIb/IIIa inhibitors,
however, may be beneﬁcial in non-ACS
Figure 3— Cumulative event-free survival from cardiovascular events in diabetic patients (n  173) with and without high platelet reactivity. The
cutoff value to deﬁne high platelet reactivity using receiver operating characteristic analysis was 62% maximum ADP (20 mol/l)-induced platelet
aggregation (Aggmax). The major adverse cardiac event rate was signiﬁcantly higher in patients with platelet reactivity above the cutoff value
compared with those below this cutoff value (37.7 vs. 13.3%, respectively; odds ratio 3.96 [95% CI 1.8–8.7]; P  0.0010). Multivariate Cox
regression analyses showed high platelet reactivity (HR 3.35 [95% CI 1.68–6.66]; P  0.001) to be the strongest independent predictor of major
adverse cardiac events. (Adapted from ref. 46.)
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gentPCIwithaspirinorclopidogrelresis-
tance. However, a subgroup analysis of
the Tailoring Treatment with Tiroﬁban in
Patients Showing Resistance to Aspirin
and/or Resistance to Clopidogrel (3T/2R)
studyfailedtoshowanysigniﬁcantdiffer-
ences associated with this strategy among
diabetic subjects (54). Another approach
to improve platelet inhibition in diabetic
patients is with the adjunctive use of
cilostazol, a phosphodiesterase III inhibi-
tor (Fig. 1). Several studies have shown
the beneﬁt of triple antiplatelet therapy
with aspirin, clopidogrel, and cilostazol,
particularly in diabetic patients treated
with bare-metal as well as drug-eluting
stents (55–56). These ﬁndings may be at-
tributed to a greater degree of platelet
inhibition achieved with adjunctive treat-
ment with cilostazol in diabetic patients,
as shown in the OPTIMUS-2 study (57).
This study showed that cilostazol, which
increases intraplatelet cAMP levels, en-
hances phosphorylation of vasodilator-
stimulated phosphoprotein (VASP),
thereby increasing P2Y12 inhibitory ef-
fects (57). However, the major drawback
of cilostazol therapy is its high prevalence
of side effects (e.g., migraine, palpita-
tions, and gastrointestinal disturbances),
which frequently lead to drug withdrawal
(57).
Use of new agents. The development of
newer antiplatelet agents that can effec-
tively and safely inhibit platelet activation
and aggregation processes appears to be
the most promising strategy in view of a
hypothetical future in which antiplatelet
drug regimens will be used according to
individual need. This may imply use of
drugs that may target pathways that are
dysfunctional in a particular patient pop-
ulation, such as subjects with diabetes.
Accordingly, picotamide has been sug-
gestedasatreatmentalternativetoaspirin
(58). Picotamide, in fact, inhibits both
thromboxaneA2synthaseandthrombox-
ane A2 receptors and, therefore, is able to
block the effect of thromboxane A2 that is
generated through COX-1 escape mecha-
nisms, which may represent a pathway
leading to an inadequate aspirin-induced
effect in diabetic patients (Fig. 1). In the
Drug Evaluation in Atherosclerotic Vas-
cularDiseaseinDiabetics(DAVID)study,
a total of 1,209 adults aged 40–75 years
with type 2 diabetes and PAD were ran-
domized to receive picotamide (600 mg
b.i.d.) or aspirin (320 mg o.d.) for 24
months(58).Thecumulativeincidenceof
the 2-year overall mortality was signiﬁ-
cantly lower among patients treated with
picotamide (3.0%) than in those who re-
ceived aspirin (5.5%), with a relative risk
ratioforpicotamideversusaspirinof0.55
(95% CI 0.31–0.98). However, although
the combined end point of mortality and
morbidity had a slightly lower incidence
in the picotamide group, this difference
did not reach statistical signiﬁcance.
Other thromboxane inhibitors, such as
ramatroban, ridogrel, and S18886, are
also currently under clinical investigation
and may represent future treatment alter-
natives (59) (Fig. 1).
There are several P2Y12 receptor an-
tagonists under advanced clinical investi-
gation (60). These include prasugrel,
ticagrelor (AZD6140), cangrelor, and eli-
nogrel (PRT128) (Fig. 1). Prasugrel and
ticagrelorareadministeredorally,cangre-
lor is for intravenous use, and elinogrel
can be administered via both routes. Pra-
sugrel is an irreversible agent, whereas ti-
cagrelor, cangrelor, and elinogrel are
reversible. All agents have increased po-
tency and are associated with less re-
sponse variability compared with
clopidogrel (60). The pharmacodynamic
and pharmacokinetic proﬁles of these
drugs and the preclinical and early-phase
clinical data go beyond the scope of this
review and are described in detail else-
where (60). Encouraging clinical out-
come data from large-scale phase III
testing is available for prasugrel (61). Pra-
sugrel is a third-generation thienopyri-
dine that, like clopidogrel, selectively and
irreversibly blocks the ADP P2Y12 recep-
tor (62). However, prasugrel has a more
favorable pharmacokinetic proﬁle be-
cause, compared with clopidogrel, it is
more efﬁciently transformed into its ac-
tive metabolite, which leads to more
prompt, potent, and predictable degrees
of platelet inhibition as shown in numer-
ouspharmacodynamicstudiesevenwhen
compared with platelet inhibition associ-
ated with both high and maintenance
dosing of clopidogrel (62). The clinical
implications of these more favorable
pharmacological properties were evalu-
atedintheTrialtoAssessImprovementin
Therapeutic Outcomes by Optimizing
Platelet Inhibition with Prasugrel–
ThrombolysisinMyocardialInfarction38
(TRITON-TIMI 38) comparing prasugrel
with clopidogrel in patients (n  13,608)
with moderate- to high-risk ACS who un-
derwent PCI (62). After a median dura-
tion of 14.5 months, the primary end
point (composite of cardiovascular death,
nonfatal myocardial infarction, or nonfa-
tal stroke) occurred in 12.1 vs. 9.9% of
clopidogrel- vs. prasugrel-treated pa-
tients, respectively (hazard ratio [HR]
0.81; P  0.001). However, there was an
increased risk of major bleeding observed
in2.4%ofthepatientsreceivingprasugrel
compared with 1.8% of the patients re-
ceiving clopidogrel (HR 1.32; P  0.03).
Despite the increased bleeding risk, the
prespeciﬁed net clinical beneﬁt analysis,
deﬁned as the composite of efﬁcacy and
bleeding end points, still favored prasug-
rel (12.2 vs. 13.9% of prasugrel- and clo-
pidogrel-treated patients, respectively;
HR0.87;P0.004).Ofnote,thepatients
who beneﬁted most from prasugrel ther-
apy were diabetic (63). There were 3,146
subjects with a preexisting history of dia-
betes, of whom 776 were receiving insu-
lin therapy. The primary end point was
reducedsigniﬁcantlywithprasugrelindi-
abetic subjects compared with patients
without diabetes (12.2 vs. 17.0%, respec-
tively; HR 0.70; P  0.001). A beneﬁt of
prasugrel was observed in diabetic sub-
jectsoninsulin(14.3vs.22.2%;HR0.63;
P0.009)andthosenotoninsulin(11.5
vs. 15.3%; HR 0.74; P  0.009) (Fig. 4).
Myocardial infarction was reduced with
prasugrelby40%indiabeticsubjects(8.2
vs. 13.2%; HR 0.60; P  0.001). Similar
TIMI major hemorrhage rates were ob-
served in diabetic subjects receiving clo-
pidogrel or prasugrel (2.6 vs. 2.5%,
respectively; HR 1.06; P  0.81). The net
clinical beneﬁt with prasugrel was greater
for subjects with diabetes (14.6 vs.
19.2%;HR0.74;P0.001)thanwithout
diabetes (11.5 vs. 12.3%; HR 0.92; P 
0.16). The OPTIMUS-3 trial is currently
evaluating the pharmacodynamic differ-
ences between prasugrel (60-mg loading
dose and 10-mg maintenance dose) and
clopidogrel (600-mg loading dose and
150-mg maintenance dose), speciﬁcally
in patients with type 2 diabetes (clinical
trial reg. no. NCT00642174). This study
will provide mechanistic insights into the
clinical beneﬁts achieved with clopi-
dogrel observed in the TRITON-TIMI 38
study, particularly in diabetic patients.
Ultimately,antiplateletagentsthatin-
hibit targets other than COX-1 and P2Y12
are currently under advanced clinical de-
velopment. These are warranted in order
toovercomethemultitudeofstimulilead-
ing to enhanced platelet reactivity, which
characterizes diabetic patients. Thrombin
is the most potent platelet stimulus, and
thrombingenerationispronouncedindi-
abeticpatients.Severalthrombinreceptor
antagonists that block the protease-
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(E5555, SCH 530348) are currently un-
derclinicalinvestigation(64)(Fig.1).Itis
important to emphasize that thrombotic
processes are the result of not only plate-
lets but also plasmatic factors. Therefore,
a better understanding of how these plas-
matic components contribute to adverse
outcomes in high-risk patients, including
those with diabetes, is pivotal for the de-
velopmentoftailoredtreatmentstrategies
(65). Indeed, the large number of agents
speciﬁcally targeting various plasmatic
components involved in thrombotic pro-
cesses will be useful as this ﬁeld further
develops.
Conclusions
Diabeticpatientshaveanincreasedriskof
atherothrombotic events in part attrib-
uted to platelet dysfunction, which char-
acterizes this patient population. In
particular, diabetic patients have in-
creased platelet reactivity warranting use
of platelet-inhibiting strategies in order to
reduce their ischemic risk. Although cur-
rently approved antiplatelet treatment
strategies have proven useful in improv-
ing outcomes, diabetic patients continue
tohaveahigherriskofadversecardiovas-
cular events compared with that in non-
diabetic patients. Reduced antiplatelet
drug responsiveness, including resistance
to currently used oral antiplatelet agents,
has been suggested to play a role in these
worse outcomes. These ﬁndings under-
scoretheneedofindividualizedantiplate-
let treatment regimens in diabetic
patients. Novel and more potent anti-
platelet agents currently under clinical
development will be useful in efforts to
reach these therapeutic goals.
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